De Palma, Michele http://orcid.org/0000-0001-9128-5459
Hanahan, Douglas http://orcid.org/0000-0002-0883-5251
Article History
Received: 4 August 2023
Accepted: 22 April 2024
First Online: 25 June 2024
Competing interests
: None of the research results reviewed and discussed herein reflect bona fide competing interests. In the interest of full disclosure, M.D.P. has received sponsored research grants from Hoffmann La-Roche, Deciphera Pharmaceuticals, MedImmune and EVIR Therapeutics, in part to investigate angiogenesis inhibitors and immunotherapy combinations; serves on the scientific advisory boards of EVIR Therapeutics, Montis Biosciences, Macomics, Deciphera Pharmaceuticals, Light Chain Bioscience/Novimmune and Genenta; and is an inventor on patents on engineered immune cells filed by the Swiss Federal Institute of Technology in Lausanne (EPFL). D.H. has received sponsored research grants from Hoffmann La-Roche and Bristol Myers Squibb; serves on the scientific advisory boards of Pfizer Oncology, Opna Bio, 4D Molecular Therapeutics and Cellestia; and is a founder of Opna Bio, which has licensed an EPFL patent describing the RNA-binding protein FMRP as a new cancer target.